Interim report
Page 1
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com November 4, 2026 To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804 Dear Sir / Madam, Sub: Outcome of the Board Meeting held on November 4, 2026 The Board of Directors of the Company at its meeting held today, November 4 , 2026, has, inter alia, considered and approved: a) the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. b) the payment of interim dividend of 700% i.e. Rs.7.00 (Rupees seven only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has fixed November 11, 2026, as the Record Date for the purpose of payment of Interim Dividend and the same will be paid on or before November 20, 2026. c) the proposal to file a Scheme of Amalgamation for merger of Auroactive Pharma Private Limited, wholly owned subsidiary of the Company with Apitoria Pharma Private Limited, wholly owned subsidiary of the Company, with Hon’ble NCLT, Hyderabad, that has been approved by the Board of Directors of the respective companies. d) the transfer of ownership of Auro Pharma LLC, Russia, from Auro active Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company that has been approved by the Board of Directors of the respective companies.
Page 2
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com e) based on the recommendation of the Nomination and Remuneration/Compensation Committee and subject to the approval of the Members through Postal Ballot, the re-appointment of Mr. Mangalam Ramasubramanian Kumar (DIN 03628755) as a Director (Non -executive and Independent) of the Company for the second term of 5 (five) years with effect from April 1, 202 7. His first term as Non - executive and Independent Director is completing on March 31, 2027. The Board meeting commenced at 4:15 p.m. and concluded at 6:00 p.m. Please take the information on record. Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Enclosures: as above.
Page 3
A B AUROBINDO PHARMA LIMITED (CiN - L24239TG1986PLC015190) WNW aurobindo .com Regd. Office: Plot No.2, Maitrivihar , Ameerpet, Hyderabad - 500 038, India Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo .com (All amounts are in ~ million, unless otherwise stated) STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30,2026 Quarter ended Half.E!ar ended Year ended Particulars 30.09.2026 30,06.2026 30.09.2025 30.09.2026 30.09.2025 31.03 .L026 Unaudited Unaudited Unaudited Unaudited Unaudited Audited Continuing Operations: 1 Revenue from operations (a) Net sales! income from operations 31,627.9 27,816 .9 27,001.0 59,444 .8 54,709.0 1,08,537.1 (b) Other operating income 145.4 178.2 298.3 323.6 558.6 1 ,1633 Total revenue from operations 31,773 .3 27,995 .1 27,2993 59,768.4 55,2676 1,09,700.4 2 Other income (a) Forei~n exchange gain (net) 221.0 729.9 591.5 950.9 9975 1,7907 Ib) Others 807.0 1,689.0 1,003.7 2,496.0 1,435.4 4,084 .6 Total other income 1,028.0 2,418.9 1,595.2 3,446.9 2,432.9 5,875 .3 3 Total income (1+2) 32,801.3 30,414.0 28,894_5 63,215.3 57,700.5 1,15,575 .7 4 Expenses (a) Cost of materials consumed 13,809.7 12,888 .9 12,385.1 26,698.6 25,740.7 52,200 .9 (b) Purchase of stock-in-trade 13.5 - 10.5 13.5 10.5 49.0 (c) Changes in inventories of finished goods, stock ·in-t rade and work- 777.2 (480.5) 1,054.0 296.7 1,430 .9 542.4 In-progress (d) Employee benefits expense 3,000 .7 2,959.1 2,768.2 5,959 .8 5,447 .1 10,943.3 (e) Finance costs 480.9 470.7 574.4 951.6 1,174.4 2.130.7 (f) Depreciation and amortisation expenses 695.2 689.9 670.0 1,385.1 1,3259 2,676.0 (g) Other expenses 4,314 .6 3,805.1 3,868,2 8,119.7 7,4828 15,037.4 Total expenses 23,091 .S 20,333.2 21,330.4 43,425.0 42,612.3 83,579.7 5 Profit before exceptional items and tax from continuing operations (3- 9,709 .5 10,080 .8 7,564.1 19,790.3 15,088.2 31.996.0 4\ 6 Exceptional items (refer note 5) - - - 173.8 7 Profit before tax from continuing operations (5-6) 9,709 .5 10,080 .8 7,564.1 19,790.3 15,088.2 31,822.2 S Tax expense Current tax 2,477.4 2,715.0 1,744.8 5,192.4 3,627.4 7.512.3 Deferred tax (3.7) (6 .4) (3.1) (10.1) 29.7 19.6 Total tax expense 2,473 .7 2,708.6 1,741.7 5.182.3 3.657 1 7 .531.9 9 Profit after tax from continuing operations (7-8) 7.235 .8 7,372.2 5,822.4 14,60S.0 11.431.1 24,290.3 Discontinued Operations: (Refer note 4) 10 Loss before tax from discontinued operations - - (11.3) - (34.5) (186.4) 11 Tax expense from discontinued operations - - (2.6) (8.4) (44.1) 12 Loss from discontinued operations (10-11) (8.7) (26.1) (142.3) 13 Profit after tax (9+ 12) 7,235.8 7.372.2 5.813.7 14,608.0 11,405.0 24,148 .0 14 Other comprehensive income A) Items that will not to be reclassified subsequently to profit or loss: (a) Re-measurement of defined benefit liability (60.4) 3.6 (0.4) (56.S) (18.0) 14.5 (b) Income -tax relating to items that will not be reclassified to profit or 15.2 (0.9) 0.1 14.3 4.5 (3.7) loss B) Items that will be reclassified subsequently to profit or loss: a) Fair value change on derivatives designated as cash flow hedge Inet) 7S.0 - - 7S.0 - - b) Income -tax on items that will be reclassifi ed subsequent ly to profit or (19.6) - (19.6) loss Total other comprehensive income/(Ioss) (net of tax) 13.2 2.7 (0.3) 15.9 (13.5) 10.8 15 Total comprehensive income (13+14) 7,249.0 7.374.9 5,813.4 14,623.9 11,391.5 24.158.8 16 Paid-up equity share capital (face value ~ 1 per share) 575.4 575.4 580.8 575.4 580.8 580.8 17 Other equity 2,26.596.1 18 Earnings per equity share from continuing operations (face value ~ 1 per (Not annuallsed) (Not annualised) (Not annualised ) (Not annualised) (Not annualised (Annualised) sharel (a) Basic (in ~) 12.5S 12.75 10.02 25.33 19.68 41.83 (b) Diluted (in ~) 12.5S 12.75 10.02 25.33 19.68 41.83 19 Earnings per equity share from discontinued operations (face value ~ 1 (Not annualised) (Not annualised) (Not annualised) (Not annualised) (Not annualised (Annualised) Der share) (a) Basic (in ~) (0.01) (0.04) (0.25) (b) Diluted (in ~) (0.01) (0.04) (0.25) 20 Earnings per equity share for total operations (face value 'I: 1 per share) (Not annualised) (Not annualised) (Not annualised) (Not annualised) (Not annualised (Annualised) (a) Basic (in ~) 12.58 12.75 10.01 25.33 19.64 4158 bl Diluted (in ~) 12.5S 12.75 10.01 25.33 19.64 41.58 Page 1 of 4
Page 4
Standalone Balance Sheet {All ~ rn ollnts are in '{ million. unless otherwise $laced 51. Particulars As at As at No. 30.09 .2026 31.03.2026 Unaudited Audited ASSETS 1 Non-current assets Property. plant and equipment 23,783.0 23,177.6 Capital work-in-progress 2,240.6 2,285.5 Right-of-use assets 924.9 1,021.7 Goodwill 917.0 Other intangible assets 94.4 321.0 Financial assets Investments 1,75,810.7 1,68,361.5 Loans 11,588.6 12,104.5 Trade receivables - Other financial assets 503.2 490.4 Income tax assets (net) 394.9 2,902.1 Other non·current assets 1, 110.1 993.7 Total non-current assets 2,16,450.4 2.12.5750 2 Current assets Inventories 24,444.1 23.605.7 Financial assets Investments 0.3 7.262.0 Trade receivables 49,920.3 42.096.8 Cash and cash equivalents 973.9 1,604.3 Bank balances other than cash and cash equivalents 20.3 20.7 Loans 60.5 56.9 Other financial assets 225.6 32.3 Other current assets 6,096.8 5,540.1 Total current assets 81,741.8 80.218.8 TOTAL ASSETS (1+2) 298192.2 292793.8 EQUITY AND LIABILITIES 1 Equity Equity share capital 575.4 580.8 Other equity 2,33.167.3 2,26,596.1 Total equity 2,33,742.7 2.27.176.9 Liabilities 2 Non-current liabilities Financial liabilities Lease liabilities 761.0 854.1 Provisions 659.8 731.7 Deferred tax liability {netl 1032.8 1,037.6 Total non-current liabilities 2,453.6 2,623.4 3 Current liabilities Financial liabilities Borrowings 38,893.9 41,824.7 Lease liabilities 199.1 173.6 Trade payables total outstanding dues of micro enterprises and small enterprises 521.8 782.0 total outstanding dues of creditors other than micro enterprises and small enterprises 17,836.6 17,538.0 Other financial liabilities 1,903.6 1,479.7 Other current liabilities 372.4 412.4 Provisions 295.2 245.8 Current tax liabilities (net) 1,973.3 537.3 Total current liabilities 61,995.9 62,993.5 TOTAL EQUITY AND LIABILITIES (1+2+3) 298192.2 2,92793 .8 Page 2 of 4
Page 5
Standalone Statement of Cash Flows (All ~maunts ~'e I~ 't mil lion. unless other wise-stated · SI. For the half For the half No. Particulars year ended year ended 30.09.2026 30.09.2025 Unaudited Unaudited 1 CASH FLOW FROM OPERATING ACTIVITIES Net profit before tax from continuing operations 19.790.3 15.088.2 from discontinued operations - (34.5) Adjustments for: Depreciation and amortisation expenses 1.385.1 1,415.1 Allowance for expected credit losses (net) 5.8 (45.8) Unrealised foreign exchange gain (net) (1.009.7) (1.350.6) Profit on sale of property, plant and equipment (net) (210.2) (7.3) Dividend income (705.6) Profit on sale of investments (65.0) Finance costs 943.6 1.167.1 Interest income _l1648.0 (597.4 Operating profit before working capital changes 19,191.9 14,929 .2 Movements in working capital: (Increase)/decrease in trade receivables (7,247.7) 145 .6 (Increase)/decrease in inventories (1,196.5) 757.3 (Increase)/decrease in loans (3.7) (9,0) (Increase)/decrease in other financial assets (16.9) (134.0) (Increase)/decrease in other assets (700.1) 2,350.0 Increase/(decrease) in trade payables 200.3 (1.813.3) Increase/(decrease) in provision for employee benefits 41.1 269.5 Increase/(decrease) in other financial liabilities 245.5 (749.6) Increase/(decrease) in other liabilities [39.9) 211.0 Cash generated from operating activities 10,474.0 15,956.7 Income-tax paid (net) (1249.1) (3,441.0) Net cash flow generated from operating activities (A) 9,224.9 12.515 ,7 2 CASH FLOW FROM INVESTING ACTIVITIES Purchase of property, plant and equipment including movement in capital work-in- (1,550.1) (3.370 ,2) progress, capital advances and capital creditors Proceeds from sale of property. plant and equipment 6.5 188.3 Purchase of non-current investments (729.9) (10,280.0) Proceeds from redemption of debentures 1,044.8 5,500.0 Proceeds from sale of current investments (net) 7,326.8 (10.0) Proceeds from sale of business to a subsidiary (refer note 4) 1,432.1 Dividend received from subsidiaries - 705 ,6 Loans given to subsidiaries (6,820.0) (8,440 .0) Loans repaid by subsidiaries - 7,301.0 Interest received 1,229.4 1,798.1 Movement in other bank balances (net) 0.4 8.2 Net cash flow generated from/fused in) investing activities (B) 1,940.0 (6,599 .0) 3 CASH FLOW FROM FINANCING ACTIVITIES Buy back of equity shares (including transaction cost) (8,058.0) Proceeds from non current borrowings - 1,800.0 Repayment of non current borrowings (5,800.0) (1,258.3) Proceeds/(repayment) of current borrowings (net) 2,705.6 (3,536.5) Repayment of lease liabilities (120.3) (120.1) Interest paid (897,4) (1.174.5) Dividend paid (0.4) (2.321.9) Net cash used in financing activities (e) (12,170.5) (6,611.3) Net decrease in cash and cash equivalents (A+B+e) (1,005.6) (694.6) Cash and cash equivalents at the beginning of the year 1,604.3 2.952.6 Effect of exchange differences on cash and cash equivalents 375.2 95.1 Cash and cash equivalents at the end of the year 973 .9 2,353,1 Cash and cash equivalents comprises of: Cash on hand 0.1 Balance with banks 973.9 2,353.0 Cash and cash equivalents considered for cash flows 973.9 2.353 .1 Page 3 of 4
Page 6
NOTES: 1 The above unaudited standalone financial results of Aurobindo Ph arm a Limited ("the Company") has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2 The above unaudited standalone financial results of the Company as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on November 04, 2026. The results for the quarter and half year ended September 30, 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and half year ended September 3D, 2026. 3 The Company operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment" . 4 The Board of Directors of the Company at its meeting held on April 06, 2026 approved the transfer of domestic branded generiC pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement ("BTA") to Auropharm limited (previously known as Aura Pharma limited), a wholly owned subsidiary of the Company on a going concern basis w.e.f April 01, 2026. Accordingly, disclosure as required under Indian Accounting Standard (Ind AS) 105 "Non·Current Assets Held for Sale and Discontinued Operations", in the standalone financial results for all the periods have been suitably presented. Particulars Quarter ended Half year ended Year ended 3D 09 2026 30.062026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 Total income - 597.9 1,111.3 2,016,8 Total expenses 609.2 - 1,145.8 2,203.2 Loss before tax (11.3) (34.5) (186.4) Tax expenses (2.6) (8.4) (44.1) Loss for the 'period . (8.7) . (26.1) (142.3 Cash flow from discontinued operations For the half For the half year ended year ended 30.09.2026 30.092025 Cash flow generated from operating activities (35,00) Cash flow used in investing activities Cash flow used in financing activities (0.10) (35.10) 5 During the year ended March 31, 2026, the Government of India consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Government is in the process of issuing related rules. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations . The Company assessed the implications of the New Labour Codes and recognized an incremental cost of ~ 173.8 million during the vear ended March 31. 2026. 6 The Board of Directors of Company at their meeting held on April 06, 2026, approved buyback of 5,423,728 fully paid-up equity shares of face value of ~ 1 each (representing 0.93% of the total number of equity shares of the Company) for an aggregate value not exceeding ~ 8,000.0 million (buyback size) (excluding transaction cost) at a maximum buyback price of ~ 1,475 per equity share. Upon completion of the buyback, the Company extinguished the equity shares in compliance with applicable rules and regulations. Consequently, the paid·up equity share capital has been reduced by ~ 5.4 million . The aggregate amount paid for buyback is ~ 8,058 million including related expenses. 7 The Board of Directors at their meeting held on November 4, 2026 declared an interim dividend of ~ 7 per equity share (Face value ~ 1). - y.p...SKI.1,t a o -5' By Order of the Board ~ '""" A.;. rf' For Aurobindo Pharma Limited I ~ ~I) t: CHARTERED tn o ACCOUNTANTS m A. ~ ~ ~ w- . • ~ * * o ~ ~ERA\)p...O * K.Nithyan ar1 a Re<ldy Place: Hyderabad - Vice Chairman & Managing Director - Date: November 04,2026 DIN-01284195 Page 4 of 4
Page 7
Deloitte Haskins & Sells Chartered Accountants 8th & 9th floors Phase III, Block - M Meenakshi Pride Rock Survey No. 23, Gachibowli Serilingampally Municipality Ranga Reddy District Hyderabad-S00032 Telangana, India INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED 1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of AUROBINDO PHARMA LIMITED ("the Company"), for the quarter and half year ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review . 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (!CAl). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. Place: Hyderabad V te: November 04,2026 For DELOITTE HASKINS & SELLS Chartered Accountants (Firm's Registration No. 0080725) C Manish Muralidhar (Partner) (Membership No. 213649) (UDIN : 26213649TRBCUJ6507)
Page 8
AUROBINDO PHARMA LIMITED (CiN - L24239TG1986PLC015190) www aurobindo com Regd Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500038, India Tel: +91 (40) 66721200; Fax: +914023741080; Email: info@aurobindo .com JAil amounts are In ~ million, unless otherwise stated) STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 Quarter ended Half year ended Year ended Particulars 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 Unaudited Unaudited Unaudited Unaudited Unaudited Audited 1 Revenue from operations (a) Net sales/ income from operations 1,02,272.8 91,058.2 82,369.6 1,93,331.0 1,60,287.3 3,33,847.4 (b) Other operating income 360.1 445.3 487.4 805.4 1,251.1 2,683.4 Total revenue from operations 1,02,632.9 91,503.5 82,857.0 1,94,136.4 1,61,538.4 3,36,530.8 2 Other income (a) Foreign exchange gain (netl 28.5 526.2 49.8 554.7 45.9 - (blathers 1,653.7 2,1161 1,1561 3,769.8 2,209.1 4,920.9 Total other income 1,682.2 2,642.3 1,205.9 4,324.5 2,255.0 4.920.9 Total income (1+2) 1,04,315.1 94.145.8 84,062.9 1,98,460.9 1,63,793.4 3,41,451.7 3 Expenses (al Cost of materials consumed 29,802.8 28,944.0 25,098.0 58,746.8 50,449.6 1,03,051.9 (b) Purchase of stock-in-trade 9,137.6 9,317.8 8,460.5 18,455.4 16,538.5 34,779.8 (c) Changes in inventories of finished goods, stock-in-trade and work-in 893.0 (1,992.3) (1699) (1,099.3) (1,2073) (2,948.1) progress (d) Employee benefits expense 16,585.5 14,801.5 12,773.3 31,387.0 25,061.3 51,901.7 (e) Finance costs 1,022.1 1,016.6 952.4 2,038.7 1,929.9 3,8397 (f) Foreign exchange loss (netl - - 100.7 (g) Depreciation , amortisation and impairment expense 5,311.5 4,868.2 4,291.9 10,179.7 8,348.9 17,781.9 (h) Other expenses (refer note 111 24,656.5 21,621.9 19,914.1 46,278.4 37,881.1 81,187.5 Total expenses 87,409.0 78,577.7 71,320.3 1,65,986.7 1,39,002.0 2,89,695.1 4 Profit before share of profit/(Ioss) of associates and joint ventures, 16,906.1 15,568.1 12,742.6 32,474.2 24,791.4 51.756.6 exceptional items and tax (1+2-3) 5 Share of profit/(Ioss) of associates and jOint ventures. net of tax (29.4) (15.4) 16.6 (44.7) 35.8 15.2 6 Profit before exceptional items and tax (4+5) 16,876.7 15,552.7 12,759,2 32,429.5 24,827 2 51.771.8 7 Exceptional items (refer note 8 ) 4018 401.8 653.3 8 Profit before tax (6·7) 16,876.7 15,150.9 12,759.2 32,027.7 24,827.2 51,118.5 9 Tax expense Current tax 5,085.7 6,100.1 4.630.3 11,185.8 9,5375 17,361.4 Deferred tax 552.6 (1,269.5) (352.4) (716.9) (1,433.6) (1,272.6) Total tax expense 5,638.3 4,830.6 4,277.9 10,468.9 8,103.9 16,088.8 10 Profit after tax (8-9) 11,238.4 10,320.3 8,481.3 21,558.8 16,7233 35,0297 11 Other comprehensive Income AI Items that will not be reclassified subsequently to profit or loss: i) Re·measurement of defined employee benefit liability (49.5) 3.6 (6.1) (45.9) (28.0) 73.7 ii) Equity investments through other comprehensive income - net 39.9 (81.1) 8.8 (41.2) 21.1 35.5 change in fair value iii) Income-tax relating to items that will not be reclassified to profit 2.9 17.5 (0.7) 20.4 2.1 (27.0) or loss B) Items that will be reclassified subsequently to profit or loss: i) Exchange differences on translating the financial statements of 1,977.5 (408.7) 5,408.7 1,568.8 9,473.9 19.569.8 foreign ooerations ii) Fair value change on derivatives designated as cash flow hedge 78.0 - - 78.0 (netl iii) Income-tax on items that will be reclassified subsequently to (19.6) (19.6) - profit or loss Total other comprehensive income/(Ioss) (net of tax) 2,029.2 (468.7) 5,410.7 1,560.5 9,469.1 19,652.0 12 Total comprehensive income (net of tax) (10+ 11) 13,267.6 9,851.6 13,892.0 23,119.3 26,192.4 54,681.7 Attributable to: Owners of the Parent Company 13,290.0 9,856.9 13,895.2 23,147.0 26,201.1 54,699.4 Non-controlling interest (22.4) (5.3) (3.2) (27.7) (8.7) (17.7) Out of total comprehensive income above, Profit after tax attributable to: Owners of the Parent Company 11,260.8 10,325_6 8,484.5 21,586.5 16,732.0 35,047.5 Non-controlling interest (22.4) (5.3) (3.2) (27.7) (8.7) (178) Other comprehensive incomellioss) attributable to: Owners of the Parent Company 2,029.2 (468.7) 5,410.7 1,560.5 9,469.1 19,651.9 Non-controlling interest - - 0.1 13 Paid-up equity share capital (face value ~ 1 per share) 575.4 575.4 580.8 575.4 580.8 580.8 14 Other equity 3,78,328.9 15 Earnings per equity share (face value '0: 1 per share) (Not annualised (Not annualised (Not annualised) (Not annualised (Not annualised) (Annualised) (a) Basic (in ~) 19.57 17.86 14.61 37.52 28.81 60.34 lib) Diluted (in ~) 19.57 17.86 14.61 37.52 28.81 60.34 \,l.., •• - Page 1 of 5
Page 9
Consolidated Balance Sheet [All amounts are in 'mill iM. unless otherwise stated} 51. As at As at No . Particulars 30.09 .2026 31.03.2026 Unaudited Audited ASSETS 1 Non-current assets Property. plant and equipment 1,48,297.6 1,39,552 .0 Capital work-in-progress 34,870.6 30,088.3 Right-of-use assets 4,618.4 3,747 .3 Goodwill 12,686.2 8,00 1.5 Other intangible assets 34,046.4 22,765.0 Intangible assets under development 14,505.0 22,047.3 Investments accounted for using the equity method 1,413.4 1,088.4 Financial assets Investments 1,835.5 1,950 .4 Loans 72.5 75.7 Trade receivables 0.1 - Other financial assets 4,271.5 5,499.0 Deferred tax assets (net) 15,588.7 14,835.9 Non- current tax assets (net) 1,912.8 4,524 .3 Other non-current assets 3837.6 3758.9 Total non-current assets 2,77,956.3 2,57,9340 2 Current assets Inventories 1,31,244.2 1,20,529.4 Financial assets Investments 286.5 7,472.4 Trade receivables 75,435.3 70,943.7 Cash and cash equivalents 62,315.1 71,914 .0 Bank balances other than cash and cash equivalents 37,177.6 26,788.9 Loans 183.1 178.7 Other financial assets 2,269.0 1,009 .5 Current tax assets (net) 200.0 216 .8 Other current assets 30475.8 28.0341 Total current assets 3,39,586.6 3,27,087 .5 TOTAL ASSETS (1+2) 617 542.9 585 .021.5 EQUITY AND LIABILITIES 1 Equity Equity share capital 575.4 580.8 Other equity 393423.6 378328 .9 Equity attributable to owners of the Parent Company 3,93,999.0 3,78,909 .7 Non-controlling interest (19.0) (81.6\ Total equity 3,93,980.0 3,78,828 .1 Liabilities 2 Non-current liabilities Financial liabilities Borrowings 9,819.3 8,027.5 Lease liabilities 2,732.3 2,929.4 Others 2,424.6 2,418 .7 Provisions 3,769.1 4,004.1 Deferred tax liabilities (net) 3,015.9 3,060 .0 Other non-current liabilities 5,130.0 5363.6 Total non-current liabilities 26,891.2 25,803.3 3 Current liabilities Financial liabilities Borrowings 72,518.2 68,734 .5 Lease liabilities 1,227.9 1,037.0 Trade payables total outstanding dues of micro enterprises and small enterprises 1,563.6 1,918.8 total outstanding dues of creditors other than micro enterprises and small enterprises 57,360.3 53,753 .9 Other financial liabilities 47,026.0 43,046.5 Other current liabilities 7,638.7 6,263.0 Provisions 4,398.1 3,530.4 Current tax liabilities (net) 4,938.9 2106 .0 Total current liabilities 1,96,671.7 1,80,390.1 TOTAL EQUITY AND LIABILITIES (1+2+3) 617542.9 5.85,021.5 Page 2 of 5
Page 10
Consolidated Statement of Cash Flows (All amounts are in ~ milli on unless otherwise -stated\ 51. For the half For the half No. Particulars year ended year ended 30.09.2026 30.09.2025 Unaudited Ul"\audited 1 CASH FLOW FROM OPERATING ACTIVITIES Net profit before tax 32,027.7 24,827 2 Adjustments for: Depreciation, amortisation and impairment expense 10,179.7 8,348.9 Allowance for expected credit losses (net) (1.9) 72.4 Liabilities no longer required written back (17.1) (15.5) Un realised exchange loss/(gain) (net) (60.1) 3,961.4 Loss/(profit) on sale of property, plant and equipment (net) (285.1) 54.9 Write-off of intangible assets under development (net) 1.8 178 Share of loss/(gain) of associates and ioint ventures 44.7 (35.8) Profit on sale of investments (65.0) (0.3) Dividend income (12.8) (10.9) Finance costs 1,930.3 1,853.1 Interest income (2660.8) (1,731.0 Operating profit before working capital changes 41,081.4 37,342.2 Movements in working capital: (Increase)/decrease in inventories (3,744.5) (6,48U) (Increase)/decrease in trade receivables 949.6 305.8 (lncrease)/decrease in other financial assets 2,062.9 341.3 (Increase)/decrease in other assets (1,686.3) (672.6) Increase/(decrease) in trade payables 1,383.9 5,5899 Increase/(decrease) in provision 583.7 1,511 7 Increase/(decrease) in other financial liabilities (2,555.3) (2,029.2) Increase/(decrease) in other liabilities 490.5 761.8 Cash generated from operating activities 38,565.9 36,669.2 Income taxes paid (net of refunds) (5734.5\ (7,818 .6) Net cash generated from operating activities (A) 32831.4 28,850.6 2 CASH FLOW FROM INVESTING ACTIVITIES Purchase of property, plant and equipment, including movement in capital work- in- progress, capital (14,301.0) (13,631.6 ) advances and capital creditors (net) Purchase of intangible assets and intangible assets under development (2,250.8) (2,135.5 ) Proceeds from sale of property, plant and equipment 565.7 87.1 Purchase of non-current investments (287.8) (120.5 ) Proceeds from sale of non-current investments - 59.1 Acquisition of subsidiaries, net of cash and cash equivalents acquired (20,139.7) (Purchase)/proceeds from sale of current investments (net) 7,251.0 (10.2 ) Movement in other bank balances (10,287.0) (8,255 .3) Dividend received 12.8 10.9 Interest received 2,414.7 1,761.9 Net cash used in investing activities (8) (37022.1 (22,234.1) 3 CASH FLOW FROM FINANCING ACTIVITIES Buy back of equity shares (including transaction cost) (8,058.0) . Changes in ownership interest in subsidiary not resulting in loss of control 90.3 Proceeds from non-current borrowings 2,318.3 3,483.4 Repayment of non-current borrowings (6,002.5) (6,382.4 ) Proceeds/(repayment) of current borrowings (net) 8,989.4 (1,885 .7) Interest paid (1,816.4) (1,795.9 ) Repayment of lease liabilities (1,477.2) (52304) Dividend paid (004) (2,321.9 ) Net cash used in financing activities (C) IS 956.5 19425.9 ) Net decrease in cash and cash equivalents (A + 8 + C) (10,147.2) (2,809.4 ) Cash and cash equivalents at the beginning of the year 71,914.0 55,6379 Effect of exchange differences on cash and cash equivalents 447.7 186.2 Cash and cash equivalents at the end of the year 62214.5 53014 .7 Cash and cash equivalents comprise of: Cash on hand 2.7 1.9 Balance with banks - in current account 24,706.2 22,927 .2 - in money market 1,310.0 1,254 .6 - in deposit account 36.296.2 29832 .7 Cash and cash equivalents 62,315.1 54,016.4 Overdraft used for cash and cash management 100.6 1,001.7 Cash and cash eauivalents considered for cash flows 62,214.5 53,014 .7 .. Page 3 of 5
Page 11
NOTES: 1 The above unaudited consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2 The above unaudited consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended. 3 The above unaudited consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on November 04, 2026. The results for the quarter and half year ended September 30, 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified opinion in respect of the limited review for the quarter and half year ended September 30,2026. 4 The Group operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment" , 5 During the half year ended September 30,2026: i) The Company, incorporated a step down subsidiary, Arrow Pharma Production SAS, France through Agile Pharma B.V" Netherlands a wholly owned subsidiary of the Company w.e.f. May 21,2026 , ii) The Company invested ~ 5.2 million to acquire 26% stake in Swarnaakshu Solar Power Private Limited, India making it an associate company w.e.f. June 25, 2026. iii) The Company, incorporated a step down subsidiary, PT Auro Pharm Indonesia through PT Aurogen Pharma Indonesia, a wholly owned subsidiary of the Company w.e.f. July 01,2026 . iv) The Company, incorporated a subsidiary, Auropharm Overseas Limited w.e.f, Aug 13, 2026. v) The Company, incorporated a step down subsidiary, Ai Biochem USA INC through Ai Biochem Labs (India) Private Limited, a wholly owned subsidiary of the Company w.e,f, Aug 26, 2026 . vi) The Company, incorporated a step down subsidiary, Avogent Lifesciences Private Limited through Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company w ,e,f, Aug 31,2026 . vii) The Group invested ~ 165.0 million to acquire stake in Garuda Renewables Private limited, India making it an associate company w.e.f. July 29, 2026 . 6 On July 30, 2025, the Company through it's wholly owned subsidiary, Aurobindo Pharma USA, Inc. entered into a definitive agreement to acquire 100% membership interest in Lannett Company LLC. On June 29, 2026 (,Acquisition date') the Company pursuant to above membership purchase agreement completed the acquisition of 100% membership interest in Lannett Company LLC along with its subsidiaries (Silarx Pharmaceuticals Inc, Kremers Urban Pharmaceuticals Inc and Cody Laboratories Inc) for a purchase consideration of ~ 23,218.3 million (USD 245 .7 million) upon satisfaction of customary closing conditions and receipt of the necessary regulatory approvals and has been consolidated with effect from that date. Hence, the results for the quarter and half year ended September 30, 2026, are not comparable to the earlier periods presented . The transaction was accounted for in accordance with Ind AS 103 (Business Combinations), and the initial accounting has been provisionally determined. The group recognised ~18,615.7 million (USD 1970 million) towards the fair value of net assets acquired and ~ 4,6027 million (USD 48.7 million) towards Goodwill . 7 The Board of Directors of the Parent Company at its meeting held on April 06, 2026 approved the transfer of domestic branded generic pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement ("BTA") to Auropharm Limited (previously known as Auro Pharma Limited), a wholly owned subsidiary of the Company on a going concern basis w e.f April 01, 2026. Accordingly, the net assets of the business have been transferred at the consideration of'( 1,432 .1 million to Auropharm Limited . Since the transaction is with the wholly owned subsidiary of the Company, there is no impact on the unaudited consolidated financial statements . Page 4 of 5
Page 12
NOTES: continued .. 8 Exceptional item: a) For the half year ended September 30, 2026 includes acquisition and related costs of'!; 401,8 million (USD 4.3 million) in relation to the acquisition of 100% membershIp interest of Lannett Company LLC. b) During the year ended March 31, 2026, the Government of India consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows~ Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform defin Iti on of wages. The Government is in the process of issuing related rules. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations. The Company assessed the implications of the New Labour Codes and recognized an incremental cost of '!; 653.3 million during the year ended Mar ch 31,2026. 9 The Board of Directors of Parent Company at their meeting held on April 06, 2026, approved buyback of 5,423,728 fully paid·up equity shares of face value of ~ 1 e~ch (representing 0.93% of the total number of equity shares of the parent company) for an aggregate value not exceeding'!; 8,000.0 million (buyback size) (excluding transaction cost) at a maximum buyback price of '!; 1,475 per equity share. Upon completion of the buyback, the parent company extinguished the equity shares in compliance with applicable rules and regulations . Consequently, the paid-up equity share capital has been reduced by'!; 504 million. The aggregate amount paid for buyback is ~ 8,058 million including related expenses. 10 During the quarter, Apitoria Pharma Private Limited (a wholly owned subsidiary of the Company). completed the acquisition of Al Biochem Labs (India) Private Limited ("Al Biochem Labs") for a consideration of '1:28,5 million . Al Biochem Labs acquired the business of Al Biochem Research (India) Private Limited for a consideration of '1:200.0 million on a slump sale basis. Further on August 26, 2026, the Company incorporated Al Biochem USA Inc. as a step-down subsidiary through Al Biochem Labs (India) Private Limited . Subsequent to the quarter-end, as on October 1, 2026, Al Biochem USA Inc acquired Membership Interest in Al Biochem Labs LLC, USA for a consideration of ~1,462.1 million. 11 During the half year, Aurobindo Pharma USA, Inc., a wholly owned subsidiary of the Company recorded net loss on derecognition of lease receivable of '1: 432.6 million (USD 4.5 million) which is included under the head "Other expenses". 12 a. On July 27, 2026, Curateq Biologics Private Limited (wholly owned subsidiary of the Company) submitted the Scheme of Amalgamation by way of merger of Auro Vaccines Private Limited (Transferor Company) with Curateq Biologics Private Limited (Transferee Company) (the 'Applicant Companies') to the National Company Law Tribunal ('NCLT') for approval. Subsequently, on August 18, 2026, the Applicant Companies received an order from the NCLT dispensing with the requirement to convene meetings of their equity shareholders, secured and unsecured creditors, and Compulsorily Convertible Debenture (CCD) holders. b. On September 18, 2026, Eugia Pharma Specialities Limited (wholly owned subsidiary of the Company) submitted the Scheme of Amalgamation by way of merger of Eugia SEZ Private Limited and Eugia Steriles Private Limited (Transferor Company) with Eugia Pharma Specialities Limited (Transferee Company) (the 'Applicant Companies') to the National Company Law Tribunal ('NCLT') for approval , Subsequently, on October 9, 2026, the Company received an order from the NCLT directing it to convene meetings of its unsecured trade creditors, while dispensing with the requirement to convene a meeting of the Applicant Company's equity shareholders. Pending regulatory approvals, no impact has been given in the results for the above. 13 The Board of Directors at their meeting held on November 4,2026 declared an interim dividend of '1: 7 per equity share (Face value '1: 1), By Order of the Board Place: Hyderabad Date :November 04,2026 Page 5 of 5 For Aurobindo Pharma Limited ~~. _ Jf K. Nit hyana~ Vice Chairman & M";"aging Director DIN-01284195
Page 13
Deloitte Haskins & Sells Chartered Accountants 8th & 9th floors Phase III, Block - M Meenakshi Pride Rock Survey No. 23, Gachibowli Serilingampally Municipality Ranga Reddy District Hyderabad-S00032 Telangana, India INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of AUROBINDO PHARMA LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its associates and joint ventures for the quarter and half year ended September 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable. 4. The Statement includes the results of subsidiaries, associates and joint ventures listed in Annexure 1. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. We did not review the interim financial information of 22 subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total assets of ~ 415,852.6 million as at September 30,2026, total revenue of ~ 59,776.9 million and ~ 117,092.6 million for the quarter and half year ended September 30, 2026 respectively, total net profit after tax of ~ 1,002.6 million and ~ 3,289.3 million for the quarter and half year ended September 30, 2026 respectively, total comprehensive income (net) of ~ 1,001.0 million and ~ 3,287.7 million for the quarter and half year ended September 30, 2026 respectively and net cash inflows of ~ 5,163.3 million for the half year ended September 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of these matters. ~\ Page 1 of 5
Page 14
Deloitte Haskins 8r. Sells 7. The unaudited consolidated financial results includes the interim financial information of 65 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of ~ 114,121.5 million as at September 30, 2026, total revenue of ~ 25,871.3 million and ~ 45,920.1 million for the quarter and half year ended September 30,2026 respectively, total profit after tax (net) of ~ 558.9 million and ~ 716.5 million for the quarter and half year ended September 30, 2026 respectively, total comprehensive profit of ~ 561.1 million and ~ 718.7 million for the quarter and half year ended September 30, 2026 respectively and net cash inflows of ~ 1,353.9 million for the half year ended September 30, 2026, as considered in the Statement. The unaudited consolidated financial results also includes the Group's share of loss after tax of ~ 29.4 million and ~ 44.7 million for the quarter and half year ended September 30, 2026 respectively and total comprehensive loss of ~ 29.4 million and ~ 44.7 million for the quarter and half year ended September 30, 2026 respectively, as considered in the Statement, in respect of 4 associates and 3 joint ventures, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group. Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management. Place: Hyderabad Date: November 04,2026 Page 2 of 5 For DELOITTE HASKINS &. SELLS Chartered Accountants (Firm's Registration No. 0080725) C Manish Muralidhar Partner (Membership No. 213649) (UDIN: 26213649VBODZK9180)
Page 15
Deloitte Haskins & Sells Annexure I to the Independent Auditor's Report on Review of Interim Consolidated Financial Results The interim unaudited consolidated financial results include results of the following entities: J.l \ S No 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 Name of Component Country Relationship Helix Healthcare B.V. The Netherlands Direct Subsidiary APL Pharma Thai Limited Thailand Direct Subsidiary Aurobindo Pharma Industria Farmaceutica Ltd Brazil Direct Subsidiary Aurobindo Pharma Produtos Farmaceuticos Brazil Direct Subsidiary Limitada All Pharma(Shanghai) Trading Co Ltd China Direct Subsidiary Aurobindo Pharma USA Inc . USA Direct Subsidiary APL Healthcare Limited India Direct Subsidiary Auro Peptides Limited India Direct Subsidiary Apitoria Pharma Private Limited India Direct Subsidiary Auroactive Pharma Private Limited India Direct Subsidiary CuraTeQ Biologics Private Limited India Direct Subsidiary AuroZest Private Limited India Direct Subsidiary Aurobindo Antibiotics Private Limited India Direct SubsidiaJ:y Eugia Pharma Specialities Limited India Direct Subsidiary GLS Pharma Limited India Direct Subsidiary TheraNyM Biologics Private Limited India Direct Subsidia ry Auropharm Limited India Direct Subsidiary (formerly known as Auro Pharma Limited) Aurobindo Pharma Foundation India Direct Subsidiary Auro Vaccines Private Limited India Stej2-Down Subsidiary Agile Pharma B.V. The Netherlands Step-Down Subsidiary Milpharm Limited United Kingdom Step-Down Subsidiary Aurobindo Pharma (Malta) Ltd Malta Step-Down Subsidiary APL Swift Services (Malta) Ltd Malta Stej2-Down Subsidiary Aurobindo Pharma (Romania) s.r.1 Romania Step-Down Subsidiary Pharmacin B.V. (Merged with Agile Pharma The Netherlands Step-Down Subsidiary B.V. w.e.f July 01,2025) Aurovitas Pharma Polska Poland Step-Down Subsidiary Generis Farmaceutica S.A. Portugal Step-Down Subsidiary Generis Phar, Unipessoal Lda Portugal Stej2-Down Subsidiary Aurobindo Pharma Otalia) S.r.1 Italy Step-Down Subsidiary Arrow Generiques SAS France Ste~-Down Subsidiary 1980 Puren Pharma GmbH Germany Germany Step-Down Subsidiary Puren Pharma GmbH & Co., KG Germany Step-Down Subsidiary Aurovitas Spain SA Spain Stej2-Down Subsidiary Aurobindo Pharma B.V. The Netherlands Step-Down Subsidiary Aurovitas Spol s.r.o Czech Republic Stej2-Down Subsidiary Apotex Europe B.V. The Netherlands Step-Down Subsidiary Aurovitas Nederland B.V The Netherlands Stej2-Down Subsidiary Sameko Farma B.V . The Netherlands Step-Down Subsidiary Leidapharm B.V. The Netherlands Step-Down Subsidiary Marel B.V. The Netherlands Step-Down Subsidiary Pharma Dossier B.V. The Netherlands Stej2-Down Subsidiary Aurobindo NV/SA Belgium SteQ-Down Subsidiary CuraTeQ Biologics s.r.o . Czech Republic Step-Down Subsidiary Eugia Pharma B.V. The Netherlands Ste~-Down Subsidiary Euqia Pharma (Malta) Limited Malta Step-Down Subsidiary Euqia (UK) Limited United Kingdom Step-Down SubsidiarY Auro Pharma Inc. Canada Ste~-Down Subsidiary Aurobindo Pharma (Pty) Ltd South Africa Step-Down Subsidiary Aurobindo Pharma Japan KK Japan Ste~-Down Subsidiary Aurovida Farmaceutica SA DE CV Mexico Ste~-Down Subsidiary Aurobindo Pharma Colombia S.A.S Colombia Step-Down Subsidiary Aurogen South Africa (PTY) Ltd South Africa Stej2-Down Subsidiary Aurobindo Pharma Saudi Arabia Ltd Company Saudi Arabia Step-Down Subsidiary Aurovitas Pharma (Taizhou) Ltd China Stej2-Down Subsidiary Page 3 of 5
Page 16
Deloitte Haskins & Sells S No Name of Component 55 Aurobindo Pharma FZ-LLC 56 Aurosalud SA De CV 57 Aura PR Inc . 58 Eugia Pharma Inc. 59 Eugia Pharma (Australia) PTY Limited Country Dubai Mexico Puerto Rico Canada Australia 60 Eugia Pharma Industria Farmaceutica Limitada Brazil 61 Aurobindo Pharma Ukraine LLC Ukraine 62 Eugia Pharma Colombia S.A.S . Colombia 63 PT Aurogen Pharma Indonesia 64 Aurolife Pharma LLC USA 65 Aura Health LLC USA 66 Aura AR LLC USA 67 Aura Vaccines LLC USA 68 AuroLoqistics LLC USA 69 Acrotech Biopharma Inc USA 70 Aura Science LLC USA 71 Aura Packa9ing LLC USA 72 Vespyr Brands, LLC USA 73 Eugia Inc. USA 74 Eugia US LLC USA 75 Eugia US Manufacturing LLC USA 76 Euqia Steriles Private Limited India 77 Lyfius Pharma Private Limited India 78 Qule Pharma Private Limited India 79 Eugia SEZ Private Limited India 80 Aura Pharma LLC Russia 81 Purple Bellflower South Africa South Africa 82 Ace Laboratories Limited United Kingdom 83 Cresedemo Pharma LLC USA (w.e.f. June 13 2025) 84 Curateq Biologics B.V The Netherlands (w.e.f May 28, 2025) 85 Aurobindo Pharma (Malaysia) SDN. BHD . Malaysia (w.e.f September 17 2025) 86 CuraTeQ Biologics (Malta) Limited Malta (w.e.f September 26 2025) 87 Aurobindo Pharma Chile SpA Chile Cw.e.f October 07 2025) 88 Eugia Pharma Chile SpA Chile (w.e.f October 07,2025) 89 Aurobindo Pharma Philippines Inc Philippines (w.e.f January 23 2026) 90 Diadame Pharma SARL Senegal Cw.e.f January 1 2026) 91 Engenra Biologics Private Limited India Cw.e.f February 24 2026) 92 Arrow Pharma Production SAS France (w.e.f. May 21 2026) 93 Lannett Company LLC USA Cw.e.f June 29 2026) 94 Silarx Pharmaceuticals Inc USA (w.e.f June 29 2026) 95 Kremers Urban Pharmaceuticals Inc USA Cw.e.f June 29 2026) 96 Cody Laboratories Inc USA (w.e.f June 29 2026) 97 Auropharm Overseas Limited India Cw.e.f Auq 13 2026) Avogent Lifesciences Private Limited 98 (w.e.f Aug 31, 2026) India Page 4 of 5 Relationship Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Direct Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down Subsidiary Step-Down SLibsidiary Step-Down Subsidiary Direct subsidiary Step-Down Subsidiary
Page 17
Deloitte Haskins & Sells S No Name of Component 99 A1 Biochem Labs (India) Private Limited (w.e.f July 23, 2026) 100 A1 Biochem USA Inc (w.e.f August 26 2026) 101 PT Auro Pharm Indonesia (w.e.f July 1 2026) 102 Luoxin Aurovitas Pharm (Chengdu) Co. Ltd . 103 Raidurgam Developers Limited 104 Tergene Biotech Limited 105 NVNR (Ramannapet I) Power Plant Private Limited 106 NVNR (Ramannapet II) Power Plant Private Limited 107 Swarnaakshu Solar Power Private Limited (w.e.f June 25, 2026) 108 Garuda Renewables Private Limited (w.e.f July 29,2026) Country Relationship India Step-Down Subsidiary USA Step-Down Subsidiary Indonesia Step-Down Subsidiary China Joint venture India Joint venture India Joint venture India Associate India Associate India Associate India Associate Page 5 of 5